Likewise, our in-silico interactome proposed that POM121, beyond the transcription factors described, binds oncogenic drivers of CRC (e.g., APC) and clinical immune checkpoints (e.g., CTLA4). The gene discussed is CTLA4; the disease is colorectal carcinoma.